SPORE in Lymphoma

淋巴瘤中的孢子

• 批准号: 8321631
• 负责人: STEVEN H BERNSTEIN
• 金额: $ 229.93万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8321631
• 关键词: Arizona; B-Cell NonHodgkins Lymphoma; B-Lymphocytes; Biological Models; Biology; Cancer Center; Cells; Clinical; Clinical Trials; Correlative Study; Development; Diffuse; In Vitro; Lead; Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin' s Lymphoma; Oxidation-Reduction; Pathologic; Proteasome Inhibitor; Research Personnel; Research Project Grants; Resistance; Resources; Southwest Oncology Group; Therapeutic; Therapeutic Agents; Time; Translational Research; Universities; aurora kinase; base; design; novel; programs

This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include: Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma, Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL. Project 3: Potentiating Proteasome Inhibitor Activity in NHL. Project 4: Characterization of Lymphoma-lnitiating Cells.

这个淋巴瘤孢子应用程序从詹姆斯P.威尔莫特癌症中心（JPWCC），罗切斯特大学，和亚利桑那州癌症中心（ACC），亚利桑那大学提供了一个广泛的基础，转化研究计划，研究淋巴瘤生物学中的几个主要悬而未决的问题。具体而言，这些项目将集中在几种新型的，有针对性的治疗药物，无论是在开发或批准用于治疗三种最常见的非霍奇金淋巴瘤，即弥漫性大B细胞淋巴瘤，滤泡性淋巴瘤和套细胞淋巴瘤。我们将首先在体外和精心开发的模型系统中寻求阐明作用和/或耐药性机制;然后设计并进行以相关研究为重点的试点临床试验，以验证这些机制。JPWCC和ACC的调查人员是长期合作者，负责每个项目。西南肿瘤组淋巴瘤委员会的临床和病理资源也被整合到这个计划中。项目包括： 研究项目1：靶向极光激酶在侵袭性B细胞非霍奇金淋巴瘤， 项目2：优化氧化还原调节作为NHL的治疗策略。 项目3：增强蛋白酶体抑制剂在NHL中的活性。 项目4：淋巴瘤引发细胞的表征。

项目成果

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

• DOI: 10.1158/1078-0432.ccr-11-2413
• 发表时间: 2012-04-15
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Mahadevan D;Stejskal A;Cooke LS;Manziello A;Morales C;Persky DO;Fisher RI;Miller TP;Qi W
• 通讯作者: Qi W

Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide.

• DOI: 10.1371/journal.pone.0008115
• 发表时间: 2009-12-02
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Skalska J;Brookes PS;Nadtochiy SM;Hilchey SP;Jordan CT;Guzman ML;Maggirwar SB;Briehl MM;Bernstein SH
• 通讯作者: Bernstein SH

Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.

• DOI: 10.1309/ajcp2z0tagmuyjeb
• 发表时间: 2013-02
• 期刊: American journal of clinical pathology
• 影响因子: 3.5
• 作者: Valentino C;Kendrick S;Johnson N;Gascoyne R;Chan WC;Weisenburger D;Braziel R;Cook JR;Tubbs R;Campo E;Rosenwald A;Ott G;Delabie J;Jaffe E;Zhang W;Brunhoeber P;Nitta H;Grogan T;Rimsza L
• 通讯作者: Rimsza L

Update on aurora kinase inhibitors in gynecologic malignancies.

• DOI: 10.2174/157489208786242322
• 发表时间: 2008-11
• 期刊: Recent patents on anti-cancer drug discovery
• 影响因子: 2.8
• 作者: Tao X;Chon HS;Fu S;Kavanagh JJ;Hu W
• 通讯作者: Hu W

Liquefaction and Rupture of Angiomyolipoma after Embolization.

栓塞后血管肌瘤的液化和破裂。

• DOI: 10.1016/j.jvir.2020.05.021
• 发表时间: 2020-12
• 期刊: Journal of vascular and interventional radiology : JVIR
• 作者: Uzzo RN;Drevik J;Panaro J;Geynisman DM
• 通讯作者: Geynisman DM